Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1988-09-29
1991-11-26
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514534, 514548, 514550, 514562, 514563, 514565, 514567, 514628, 514658, 514825, 514916, 558 44, 558 47, 560 12, 560 13, 560 22, 560 25, 560 27, 560 29, 560 30, 560 34, 560 45, 560 47, 560 48, 562430, 562432, 562433, 562435, 562437, 562438, 562439, 562454, 564192, 564212, 564213, A01N 3700, A01N 3712, A01N 3707, A61K 3122, C07C30300, C07C26100
Patent
active
050682504
ABSTRACT:
Compounds such as 1-(4-bromoacetamidobenzyl)-5-methoxy-2-methylindole-3-acetic acid, N-(4-bromoacetamidophenyl) anthranilic acid and N-(3-bromoacetamidophenyl) anthranilic acid function as irreversible ligands for nonsteroidal antiinflammatory drug (NSAID) and prostaglandin binding sites. It is therefore expected that these compounds, and analogs thereof, will have utility as anti-inflammatory drugs, as affinity labeling agents and as ligands for use in affinity chromatography.
REFERENCES:
patent: 3778470 (1973-12-01), Sallmann et al.
patent: 3906662 (1990-03-01), Hashimoto et al.
patent: 4166128 (1979-08-01), Sone et al.
patent: 4250192 (1981-02-01), Sallmann et al.
patent: 4370486 (1983-01-01), Harnisch
patent: 4832697 (1989-05-01), Rose et al.
patent: 4833247 (1989-05-01), Krause
patent: 4859206 (1989-04-01), Rose et al.
Chemical Abstract, vol. 62, 16138g, Scherrer, 1965, "N-(2,3-Dimethylphenyl)-Anthronillic Acid and Its Salts".
Penning, J. Pharm. Sci., vol. 74, 651-654 (1985).
Smithgall & Penning, Biochem. Pharmacol., vol. 34, 831-835 (1985).
Penning et al., Steroids, 47, 221-247 (1986).
Penning & Sharp, Biochem. Biophys. Res. Commun., vol. 148, 646-652 (1987).
Kulmacz & Lands, J. Biol. Chem., 260, 12572-12578 (1985).
Vane, J. R.: Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs. Nature New Biol., 231, 232-235 (1971).
Smith, J. B. and Willis, A. L.: Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol., 231, 235-239 (1971).
Roth, G. J., Stanford, N., Jacobs, J. W. and Majerus, P. W.: Acetylation of prostaglandin synthetase by aspirin. Purification and properties of acetylated protein from sheep vesicular gland. Biochemistry, 16, 4244-4248 (1977).
Roth, G. J. and Siok, C.: Acetylation of the NH.sub.2 -terminal serine of prostaglandin synthetase by aspirin. J. Biol. Chem., 253, 3782-3784 (1978).
Van Der Ouderaa, F. J., Buytenhek, M., Nugteren, D. H. and Van Dorp, D. A.: Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur. J. Biochem., 109, 1-8 (1980).
Rome, L. H. and Lands, W. E. M.: Structural requirements for time dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Natl. Acad. Sci., 72, 4863-4865 (1975).
Stanford, N., Roth, G. J., Shen, T. Y. and Majerus, P. W.: Lack of covalent modification of prostaglandin synthetase (cyclo-oxygenase) by indomethacin. Prostaglandins, 13, 669-675 (1977).
Cushman, D. W. and Cheung, H. S.: Effect of substrate concentration on inhibition of prostaglandin synthetase of bull seminal vesicles by anti-inflammatory drugs and fenamic acid analogs. Biochem. Biophys. Acta., 424, 449-459 (1976).
Taylor, R. J. and Salata, J. J.: Inhibition of prostaglandin synthetase by tolmetin (tolectin, McN-2559), a new non-steroidal anti-inflammatory agent. Biochem. Pharmacol., 25, 2479-2484 (1976).
Smith, W. L.: Flurbiprofen-Sepharose chromatography of the prostaglandin synthetase from bovine seminal vesicles. Prostaglandins, 10, 983-990 (1975).
DiPasquale, G., and Mellace, D.: Inhibition of arachidonic acid induced mortality in rabbits with several nonsteroidal anti-inflammatory drugs.
Smith, M. J. H.: Prostaglandins and aspirin: an alternative view. Agents and Actions, 5/4, 315-317 (1975).
Vargaftig, B. B.: Salicylic acid fails to inhibit generation of thromboxane A.sub.2 activity in platelets after in vivo adminstration to the rat, J. Pharm. Pharmac., 30, 101-104 (1978).
Siegel, M. I., McConnell, R. T., and Cuatrecasas, P.: Aspirin-like drugs interfere with arachidonate metabolism by inhibition of 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway. Proc. Natl. Acad. Sci. USA 76, 3774-3778 (1979).
Higgs, G. A., Salmon, J. A., Henderson, B., and Vane, J. R.: Pharmcokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and anti-inflammatory activity, Proc. Natl. Acad. Sci. USA, 84, 1417-1420 (1987).
Winter, C. A. and Nuss, G. W.: Treatment of adjuvant arthritis in rats with anti-inflammatory drugs, Arthritis and Rheumatism, 9, 394-404 (1966).
Kaltenbronn, J. S., Scherrer, R. A., Short, F. W., Jones, E. M., Beatty, H. R., Saka, M. M., Winder, C. V., Wax, J. and Williamson, W. R. N.: Structure-activity relationships in a series of anti-inflammatory N-arylanthranilic acids. Arzniem-Forsch./Drug Res., 33, 621-627 (1983).
Penning, T. M. and Talalay, P.: Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins, Proc. Natl. Acad. Sci. USA, 80, 4504-4508 (1983).
Penning, T. M. and Sharp, R. B.: Prostaglandin dehydrogenase activity of purified rat liver 3-alpha-hydroxysteroid dehydrogenase, Biochem. Biophys. Res. Commun., 148, 646-652 (1987).
Hansen, H. S.: Inhibition by indomethacin and aspirin of 15-hydroxyprostaglandin dehydrogenase in vitro. Prostaglandins, 8, 95-105 (1974).
Pace-Asciak, C. and Cole, S.: Inhibitors of prostaglandin catabolism. I. Differential sensitivity of 9-PGDH, 13-PGR and 15-PGDH to low concentrations of indomethacin. Experientia, 31, 143-145 (1975).
Tai, H.-H., Tai, C. L. and Yuan, B.: 9-Hydroxyprostaglandin dehydrogenase from rat kidney. Purification to homogeneity and partial characterization, J. Biol. Chem., 255, 7439-7443 (1980).
Hansen, H. S.: 15-Hydroxyprostaglandin dehydrogenase. A review. Prostaglandins, 12, 647-679 (1976).
Magous, R., Bali, J-P., Escale, R., Girard, J-P., Rechencq, E. and Rossi, J-C.: Evidence for the existence of high affinity binding sites for indomethacin on human platelets. Mol. Pharmacol., 29, 39-44 (1985).
Murdock, G. L., Chin, C-C., Offord, R. B., Bradshaw, R. A. and Wayrren, J. C.: Human placental estradiol 17B-dehydrogenase: identification of a single histidine residue affinity-labeled by both 3-bromoacetoxyestrone and 12-beta-bromoacetoxy-4-estrene-3,17-dione, J. Biol. Chem., 19, 11460-11464 (1983).
Simons, S. S., Pumphrey, J. G., Rudikoff, S., Eisen, H. J.: Identification of cysteine 656 as the amino acid of hepatoma tissue culture cell glucocorticoid receptors that is covalently labeled by dexamethasone 21-mesylate, J. Bio. Chem., 262, 9676-9680 (1987).
Penning, T. M., Carlson, K. E. and Sharp, R. B.: Affinity-labelling of the anti-inflammatory drug and prostaglandin binding site of 3-alpha-hydroxysteroid dehydrogenase of rat liver cytosol with 17-beta- and 21-bromoacetoxysteroids, Biochem. J., 245, 269-276 (1987).
Siegal, M. I., McConnell, R. T., Porter, N. A., and Cuatrecasas, P.: Arachidonate metabolism via lipoxygenase and 12L-hydroperoxy-5,8,10,14-eicosatetraenoic acid peroxidase sensitive to anti-inflammatory drugs. Proc. Natl. Acad. Sci. USA, 77, 308-312 (1980).
Askonas Leslie J.
Penning Trevor M.
Covington Raymond
Raymond Richard L.
Trustees of University of Pennsylvania
LandOfFree
Irreversible ligands for nonsteroidal antiinflammatory drug and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Irreversible ligands for nonsteroidal antiinflammatory drug and , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Irreversible ligands for nonsteroidal antiinflammatory drug and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2386114